Eris Lifesciences Limited
Eris Lifesciences Limited is an Indian listed company in the Pharmaceuticals & Biotechnology industry (Healthcare sector), traded under NSE: ERIS and BSE: 540596 (ISIN INE406M01024).
It has a market capitalisation of ₹15,518 crore, a last close of ₹1,120 on 2026-10-19, a one-year return of -29.8%.
Valuation: a price-to-earnings ratio of 24.10x, a price-to-book ratio of 3.98x, a dividend yield of 0.6%.
Profitability: return on equity of 18.3%, return on capital employed of 15.2%, an operating margin of 35.3%.
Growth: sales growth of 22.9% a year over three years, net profit growth of 17.5% a year over three years.
Balance sheet and ownership: debt-to-equity of 0.59x, promoter holding of 54.7%.
| Metric | Value |
|---|---|
| Market capitalisation | 15,518 |
| Last close | ₹1,120 |
| P/E (TTM) | 24.10x |
| P/B | 3.98x |
| Dividend yield | 0.6% |
| ROE (FY) | 18.3% |
| ROCE (FY) | 15.2% |
| Operating margin (TTM) | 35.3% |
| Sales growth, 3-year CAGR | 22.9% |
| Profit growth, 3-year CAGR | 17.5% |
| Debt / equity | 0.59x |
| Promoter holding | 54.7% |
| 1-year return | -29.8% |
Loading the live page with the price chart, financial history, shareholding and recent filings. Data is end-of-day and rebuilt nightly; nothing here is investment advice. Financial statements · What each metric means